Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    NCT01586520
Previous Study | Return to List | Next Study

Diagnosing Thyroid Cancer Using a Blood Test

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01586520
Recruitment Status : Completed
First Posted : April 26, 2012
Last Update Posted : September 15, 2017
Information provided by (Responsible Party):
Newcastle-upon-Tyne Hospitals NHS Trust

Brief Summary:
Thyroid cancer is a relatively rare disease but its incidence is increasing in many countries.. Early and accurate diagnosis leading to earlier treatment and intervention is recognised as a major factor in determining a good outcomes. This study will investigate new ways of diagnosing thyroid cancer from blood samples using proteomic and genetic markers. The study will take samples from patients with differentiated thyroid cancer and measure relative quantities of 1000s of proteins within the blood. These measures will be explored to see if, when used in combination they can accurately diagnose thyroid cancer. If successful this technique could be extended to routine screening and could replace more invasive tests currently used. Participants will be required to supply a small sample of blood, answer questions on their medical history and also consent for their medical records to be examined. A lifestyle questionnaire will also be supplied to each participant. In the case where a diagnosis is predicted for a condition the participant was not aware of the medical team will discuss the best interests of the patient with their GP and if required refer them to a suitable specialist. The study will run for 24 months and will routinely process around 15 and 20 participants with a history of thyroid cancer per month. All patient details will be kept confidential and only non identifiable information will leave the clinic. The work will be published and if successful will be validated on another site, commercialised and made available for routine clinical use.

Condition or disease
Differentiated Thyroid Cancer

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 400 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Diagnosing Thyroid Cancer Using a Blood Test
Study Start Date : April 2011
Actual Primary Completion Date : October 2014
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid

Disease positive
Imaging or biopsy evidence of disease
Disease negative
No evidence of disease

Primary Outcome Measures :
  1. Proteomic markers of differentiated thyroid cancer [ Time Frame: 24 months ]
    The primary objective of the study is to derive molecular (proteomic) diagnostic signatures that that can distinguish patients with recurrent / residual thyroid cancer from those with no residual disease.

Secondary Outcome Measures :
  1. Genetic markers of diffferentiated thyroid cancer [ Time Frame: 24 months ]
    The secondary objective is to identify genetic markers of thyroid cancer status (recurrent / residual disease versus no disease) from peripheral blood samples. Information from the proteomics component of the study are expected to identify multiple potential protein markers. Genes encoding these differentially expressed proteins will be sequenced and will guide our team as to which genetic markers in peripheral blood may be targeted in order to improve the diagnostic power of molecular testing.

Biospecimen Retention:   Samples With DNA
serum, DNA and RNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
400 patients attending the regional thyroid cancer clinic (Northern Centre for Cancer Care) over 24 months will be recruited.

Inclusion Criteria:

  1. Age over 18 years.
  2. Patient has thyroid cancer.
  3. Patient is judged as being capable of understanding the information sheet and of giving informed consent (Mental Capacity Act 2005).
  4. Responsible clinician is approached and is happy for the patient to be included in the study.

Exclusion Criteria:

  1. Age of less than 18 years.
  2. Patient has additional risk infections (HIV, Hep B/C)
  3. Patient is involved in other medicinal or treatment based clinical trial at the time of recruitment or in the previous 4 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01586520

Layout table for location information
United Kingdom
Sir Bobby Robson Cancer Researhc Unit
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE7 7DN
Sir Bobby Robson Cancer Research Unit, Northern Centre for cancer care
Newcastle upon Tyne, United Kingdom, NE7 7DN
Sponsors and Collaborators
Newcastle-upon-Tyne Hospitals NHS Trust
Layout table for additonal information
Responsible Party: Newcastle-upon-Tyne Hospitals NHS Trust Identifier: NCT01586520    
Other Study ID Numbers: 5559
First Posted: April 26, 2012    Key Record Dates
Last Update Posted: September 15, 2017
Last Verified: September 2017
Keywords provided by Newcastle-upon-Tyne Hospitals NHS Trust:
thyroid cancer, papillary, follicular, proteomics, genetic markers
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms